



Living Cell Technologies Limited

COMPANY ANNOUNCEMENT

- In response to overwhelming public queries, clinician investigator reports progress on Living Cell Technologies' (LCT's) Diabetes Trial in New Zealand
- First patient has no ill effects and reduces daily insulin dose at early follow up

First Patient In Living Cell Technologies' New Zealand DIABECCELL[®] Trial Drops Insulin Dose Without Ill Effects

4 December 2009: Sydney, Australia, Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) is pleased to draw attention to the report that the first patient to receive an implant of DIABECCELL[®] in New Zealand is progressing well. Dr John Baker, Endocrinologist and Principal Investigator at the Centre for Clinical Research and Effective Practice (CCRep), Middlemore Hospital, reported today that the patient with type 1 diabetes, who received LCT's encapsulated insulin producing porcine cells on 6 October, has reduced his insulin dose and suffered no ill effects to date.

In response to numerous queries from the public, CCRep released their statement reporting that the 48-year-old man, with type 1 diabetes for 20 years, had started to drop his daily insulin dose by 30% while maintaining his usual blood glucose levels. Clinical details are limited as the trial is still at an early stage and was designed to keep the Principal Investigator unbiased and blinded to selected clinical information.

Prof Bob Elliott, LCT Medical Director said, "I am delighted by the response of this first patient. The clinical results are consistent with what I expected to see at this very early stage in the trial."

Dr Paul Tan, Chief Executive Officer LCT said: "In clinical trials, DIABECCELL[®] is showing very satisfying progress with positive results first from Russia and now from New Zealand."

A second New Zealand patient is to receive the DIABECCELL[®] implant in December and two more patients early in the New Year all of whom will then have received the dose of 10,000 islet equivalents per kilogram body weight (IEQ/kg). A further four patients would follow with the top dose of 15,000 IEQ/kg in this trial.

DIABECCELL[®] is designed to normalize blood glucose levels in type 1 diabetes sufferers. DIABECCELL[®] comprises encapsulated porcine insulin-producing cells which can be administered without the need to use immunosuppressive drugs.

Type 1 diabetes occurs when the body's own immune system destroys the insulin-producing cells of the pancreas (called beta cells). Five to 10 percent of the more than 200 million diabetics worldwide have insulin dependent type 1 diabetes. Type 1 diabetes is associated with kidney failure, blindness, nerve damage, life-threatening cardiovascular disease and limb amputations. Current treatment options include multiple daily injections of insulin.



For further information: www.lctglobal.com

Dr. Paul Tan
Chief Executive Officer
Mob: 021 608 784 (NZ)
Tel: +64 9 276 2690
ptan@lctglobal.com

Mr John Cowan
Finance & Administration Manager
Tel: +64 9 276 2690
jcowan@lctglobal.com

Prof. Bob Elliott
Medical Director
Mob: +64 27 292 4177
Tel: +64 9 276 2690
belliott@lctglobal.com

Paul Dekkers
Investor and Media Relations
Tel: +612 9237 2800
pdekkers@bcc.com.au

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.